Similar articles

• Margetuximab in HER2-positive metastatic breast cancer.

  Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Gradishar WJ, et al. Future Oncol. 2023 May;19(16):1099-1112. doi: 10.2217/fon-2022-1040. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170847 Review.
• FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.

  Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, Shetty KA, Kraft J, Qiu J, Song P, Charlab R, Yu J, King KE, Rastogi A, Janelsins B, Weinberg WC, Clouse K, Borders-Hemphill V, Brown L, Gomez-Broughton C, Li Z, Nguyen TT, Qiu Z, Ly AT, Chang S, Gao T, Tu CM, King-Kallimanis B, Pierce WF, Chiang K, Lee C, Goldberg KB, Leighton JK, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L. Royce M, et al. Clin Cancer Res. 2022 Apr 14;28(8):1487-1492. doi: 10.1158/1078-0432.CCR-21-3247. Clin Cancer Res. 2022. PMID: 34916216 Free PMC article. Clinical Trial.
• Clinical development and current role of margetuximab for the treatment of breast cancer.

  Tarantino P, Uliano J, Morganti S, Giugliano F, Crimini E, Curigliano G. Tarantino P, et al. Drugs Today (Barc). 2021 Sep;57(9):551-558. doi: 10.1358/dot.2021.57.9.3319148. Drugs Today (Barc). 2021. PMID: 34586103
• Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-184. Med Lett Drugs Ther. 2020. PMID: 33429416 No abstract available.
• Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.

  Nur Husna SM, Wong KK. Nur Husna SM, et al. Mol Immunol. 2022 Dec;152:45-54. doi: 10.1016/j.molimm.2022.10.005. Epub 2022 Oct 20. Mol Immunol. 2022. PMID: 36272249 Review.